![]() |
市場調查報告書
商品編碼
1306532
冠狀動脈球囊導管的全球市場:規模,佔有率,COVID-19影響分析(2023年~2029年):MedCore,各類型(PTCA,藥物釋放型,特殊球囊導管)Coronary Balloon Catheters Market Size, Share & COVID19 Impact Analysis | Global | 2023-2029 | MedCore | Segmented by: Type (PTCA, Drug-Eluting & Speciality Balloon Catheter) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2022年全球冠狀動脈球囊導管市場規模將超過9.63億美元。預計該市場在預測期內將以 2.3% 的複合年增長率增長,到 2029 年將超過 11 億美元。
本報告提供全球冠狀動脈球囊導管市場相關調查,提供市場概要,以及各市場區隔,各地區趨勢,競爭情形等資訊。
In 2022, the global market for coronary balloon catheters exceeded a valuation of $963 million. Over the forecast period, it is projected to experience a compound annual growth rate (CAGR) of 2.3%, reaching a value exceeding $1.1 billion.
The comprehensive report suite encompasses the global market for coronary balloon catheters, which includes percutaneous transluminal coronary angioplasty (PTCA) balloons and specialty balloons. Specialty balloons encompass cutting and scoring balloons.
As part of our study on the global coronary balloon catheter market, iData Research has conducted a comprehensive analysis of angiography, angioplasty (or PCI), atherectomy, and catheterization procedure volumes. This analysis has been performed to enhance the accuracy of our market sizing and provide you with detailed information on procedure volumes spanning a 10-year timeframe across 70 countries. By incorporating procedure volume data, we aim to provide a comprehensive understanding of the market dynamics and trends in the coronary balloon catheter industry.
The primary purpose of coronary balloon catheters is to dilate a vessel before the insertion of a stent. The concerns surrounding late stent thrombosis have contributed to an increase in the number of pre-stent dilation procedures, thereby driving market growth. However, the widespread adoption of drug-eluting stents (DESs) has had a limiting impact on the coronary balloon catheter market. DESs have demonstrated effectiveness in reducing restenosis rates and minimizing the need for pre-stent dilation procedures. While coronary balloon catheters may still be used after DES procedures, the overall reduction in restenosis has resulted in a decrease in unit sales for both percutaneous transluminal coronary angioplasty (PTCA) and specialty balloon catheters.
Boston Scientific holds the top position in the global coronary balloon catheter market, with a strong presence in the percutaneous transluminal coronary angioplasty (PTCA) balloon segment, where it commands a majority share.
Philips entered the market by acquiring Spectranetics, establishing its position primarily in the specialty balloon catheter segment, where it has secured a significant market share.
Medtronic, like other major competitors in the global coronary balloon catheter market, offers a wide range of devices in both the coronary and peripheral markets. This allows the company to strategically bundle products and leverage its position in the competitive landscape.